Search Results 21-30 of 80 for ☆보증업체 【위너보증.com / 가입코드 9122】 위너 ☆

  1. Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    Giving ixazomib with pomalidomide and dexamethasone may be an effective treatment for relapsed or relapsed/refractory multiple myeloma. Participation ...

  2. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung ...

  3. Study of bb2121 in Multiple Myeloma - Clinical Trials

    About this study. Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple ...

  4. Px Code,Supply #,Description,Unit Price 278000026,3643,KIT HEMODIALYSIS CATHETER POLYURETHANE DUAL LUMEN OVER THE WIRE SYMMETRIC TIP 14.5FRX19CM,498.12 ...

  5. Cyclophosphamide, Ixazomib, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma - Mayo Clinic

    Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with ixazomib and ...

  6. CC-4047 in Treating Patients With Myelofibrosis - Mayo Clinic

    About this study. RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing.

  7. https://www.mayoclinic.org/~/media/FD382661FD544C6CB4A38FC785855FAB

  8. A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease - Mayo Clinic

    The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these ...

  9. A Phase 2, Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence - Mayo Clinic

    A Phase 2, Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated ...

  10. Px Code,Supply #,Description,Unit Price 278000024,48589,CATH ABL THRMCL ST FJ,"5,504.00" 278000025,55648,CATH ABL CLS NON-NAV 6FX4,"1,312.00" 278000026 ...